Analyzing TriSalus Life Sciences (TLSI) & Its Peers

TriSalus Life Sciences (NASDAQ:TLSI) is one of 237 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it contrast to its peers? We will compare TriSalus Life Sciences to similar companies based on the strength of its risk, institutional ownership, dividends, valuation, analyst recommendations, profitability and earnings.

Profitability

This table compares TriSalus Life Sciences and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-206.24%	N/A	-236.83%
TriSalus Life Sciences Competitors	-568.57%	-156.88%	-27.81%

Analyst Ratings

This is a breakdown of current recommendations and price targets for TriSalus Life Sciences and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	0	0	6	2	3.25
TriSalus Life Sciences Competitors	1904	4901	9169	268	2.48

TriSalus Life Sciences presently has a consensus price target of $12.08, suggesting a potential upside of 196.89%. As a group, “Surgical & medical instruments” companies have a potential upside of 18.60%. Given TriSalus Life Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe TriSalus Life Sciences is more favorable than its peers.

Earnings & Valuation

This table compares TriSalus Life Sciences and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
TriSalus Life Sciences	$26.89 million	-$59.04 million	-1.63
TriSalus Life Sciences Competitors	$1.01 billion	$10.22 million	-6.27

TriSalus Life Sciences’ peers have higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

TriSalus Life Sciences has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, TriSalus Life Sciences’ peers have a beta of 0.47, indicating that their average share price is 53% less volatile than the S&P 500.

Institutional and Insider Ownership

2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 47.7% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 32.8% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 15.5% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

TriSalus Life Sciences beats its peers on 9 of the 13 factors compared.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.